Abstract
Atherosclerosis is a very complex procedure responsible for the development of coronary artery disease which is the leading cause of death in the civilized world. The obvious pandemic character of atherosclerosis augments the need to discover an ideal biomarker, which will be able to facilitate the clinical diagnosis of the atherosclerosis from the physicians especially in the early stages of the atherosclerotic process. Among the biomarkers that are already used there are classical ones, such as c-reactive protein, interleukins, tumour necrosis factor, apolipoproteins, fibrinogen, homocysteine, and novel promising ones such as lipoprotein-associated phospholipase, asymmetric dimethylarginine, myeloperoxidase, cathepsins and cystatin C. The possibility of combining circulating biomarkers with other methods such as non-invasive and invasive imaging is clinically attractive because this could contribute to the improved diagnosis and understanding of premature atherosclerosis pathogenesis.
Keywords: Atherosclerosis, biomarker, endothelium, inflammation, plaque, sensitivity, pandemic character, augments, apolipoproteins, dimethylarginine
Current Medicinal Chemistry
Title:Clinical Utility of Biomarkers in Premature Atherosclerosis
Volume: 19 Issue: 16
Author(s): A.-M. Kampoli, D. Tousoulis, N. Papageorgiou, Z. Pallatza, G. Vogiatzi, A. Briasoulis, E. Androulakis, C. Toutouzas, P. Stougianos, C. Tentolouris and C. Stefanadis
Affiliation:
Keywords: Atherosclerosis, biomarker, endothelium, inflammation, plaque, sensitivity, pandemic character, augments, apolipoproteins, dimethylarginine
Abstract: Atherosclerosis is a very complex procedure responsible for the development of coronary artery disease which is the leading cause of death in the civilized world. The obvious pandemic character of atherosclerosis augments the need to discover an ideal biomarker, which will be able to facilitate the clinical diagnosis of the atherosclerosis from the physicians especially in the early stages of the atherosclerotic process. Among the biomarkers that are already used there are classical ones, such as c-reactive protein, interleukins, tumour necrosis factor, apolipoproteins, fibrinogen, homocysteine, and novel promising ones such as lipoprotein-associated phospholipase, asymmetric dimethylarginine, myeloperoxidase, cathepsins and cystatin C. The possibility of combining circulating biomarkers with other methods such as non-invasive and invasive imaging is clinically attractive because this could contribute to the improved diagnosis and understanding of premature atherosclerosis pathogenesis.
Export Options
About this article
Cite this article as:
Kampoli A.-M., Tousoulis D., Papageorgiou N., Pallatza Z., Vogiatzi G., Briasoulis A., Androulakis E., Toutouzas C., Stougianos P., Tentolouris C. and Stefanadis C., Clinical Utility of Biomarkers in Premature Atherosclerosis, Current Medicinal Chemistry 2012; 19 (16) . https://dx.doi.org/10.2174/092986712800493039
DOI https://dx.doi.org/10.2174/092986712800493039 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets Current Place of Beta-Blockers in the Treatment of Hypertension
Current Vascular Pharmacology How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with the Metabolic Syndrome?
Vascular Disease Prevention (Discontinued) Pharmacological and Biological Activities of Benzazepines: An Overview
Current Bioactive Compounds An Artificial Immune Network Based Algorithm for Diabetes Diagnosis
Protein & Peptide Letters Resveratrol Targets in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders
Current Vascular Pharmacology Dietary Lutein and Zeaxanthin in the Prevention of Age-Related Macular Degeneration in the Elderly
Current Nutrition & Food Science Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management
Cardiovascular & Hematological Disorders-Drug Targets Severe Hyponatremia and Other Electrolyte Disturbances Associated with Indapamide
Current Drug Safety Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews B-Type Natriuretic Peptide for Diagnosis and Therapy
Recent Patents on Cardiovascular Drug Discovery Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design Withdrawal Notice: Management of Right Atrial Thrombus. Where is the Evidence? : A Narrative Review
Current Cardiology Reviews Alterations of the Kidney Cortex Proteome in Response to Exercise Training in Normoglycemic and Hyperglycemic Conditions
Current Topics in Medicinal Chemistry Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews A Review of the English and Russian Language Literature on the Osteoarticular Manifestations of Brucellosis Infection
Current Rheumatology Reviews